

REPLIMUNE

# Replimune summary

2

- Set up by the team that developed TVEC prior to sale to Amgen with the belief that TVEC was the start of what's possible, not all or the best that's possible
- Includes as stand alone agents and in combination with other therapies including radiation and immune checkpoint blockade
- Aiming to develop the best possible oncolytic immunotherapies for both stand alone and combination use

# Replimune summary

3

- Set up by the team that developed TVEC prior to sale to Amgen with the belief that TVEC was the start of what's possible, not all or the best that's possible
- Includes as stand alone agents and in combination with other therapies including radiation and immune checkpoint blockade
- Aiming to develop the best possible oncolytic immunotherapies for both stand alone and combination use
- Believe that oncolytic immunotherapy is likely to be the most effective, and is certainly likely to be the most practical, approach to generate patient specific anti-tumor immune responses to neoantigens
  - Off the shelf *in situ* generation of a tumor specific vaccine directly in the patient, in addition to the therapeutic effects of oncolysis

# Replimune summary

4

- Set up by the team that developed TVEC prior to sale to Amgen with the belief that TVEC was the start of what's possible, not all or the best that's possible
- Includes as stand alone agents and in combination with other therapies including radiation and immune checkpoint blockade
- Aiming to develop the best possible oncolytic immunotherapies for both stand alone and combination use
  
- Focusing on intra-tumoral delivery
  - Do not believe the dual hurdles for iv use of anti-virus immune responses and dilution in 5L of human blood will easily be overcome
  - With a sufficiently potent virus, do not believe iv administration is needed (“if you can biopsy it, you can inject it”), and that focusing effects on the tumor is anyway a better approach


# The Immulytic platform

5

- Uses a proprietary new high potency backbone virus, engineered for oncolytic use
- Further engineered to increase oncolytic potency and spread & to result in highly immunogenic cell death
  - Increases both local & systemic efficacy
- The platform (RP1) is then used to deliver additional immune activators directly to the tumor (RP2 & RP3 series products)
- RP1 alone effectively treats injected & uninjected tumors in rodent models
- RP1 itself is also highly synergistic with both anti-PD1 and anti-CTLA-4
- RP1 to enter the clinic mid-2017, RP2/3 mid 2018

# The Replimune pipeline

6



# Replimune Summary

7

- Checkpoint blockade combined with oncolytic immunotherapy may be the ‘golden combination’ of immuno-oncology
  - High & proven clinical synergy, but without additional toxicity
- Replimune believes this will become a ‘must have’ cornerstone approach
- Replimune has been formed by the ex-BioVex management team to develop its proprietary ‘Immulytic’ platform
- Replimune believes that Immulytic delivery of immune activating proteins directly to the immune response initiating tumor is particularly attractive
- Replimune will either ‘go it alone’ or partner with a company seeking to leverage and/or differentiate their IO portfolio

Replimune – the only company with the specific objective of exploiting the oncolytic immunotherapy/checkpoint blockade axis to the full